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Identity 
Other names: HHM, osteostatin, PLP, PTHR, 
PTHRP 




PTHLH is encoded by a single gene that is highly 
conserved among species.  
The gene is composed of 7 exons spanning a region 
of 13899 bases (start: 28002284 bp from pter; end: 
28016183 bp from pter). 
Orientation: minus strand. 
The genomic DNA for the PTHLH gene was isolated 
from a human placental genomic library (Yasuda et 
al., 1989). 
Transcription 






Size: 177 amino acids, 20194 Da. 
The PTHLH gene has seven exons, and its transcripts  
are processed by alternative splicing into three 
isoforms, encoding proteins with 139, 173 and 141 
amino acid. The pattern of expression of PTHLH 
mRNA isoforms may be cell type-specific (Sellers et 
al., 2004). Although different tumors may have 
different PTHLH splicing patterns, there are no 
tumor-specific transcripts (Southby et al., 1995). 
PTHLH is processed into a set of distinct peptide 
hormones by endoproteolytic cleavage of the initial 
translation products: mature N-terminal, mid-region 
and C-terminal secretory peptides, each having its 
own distinct function. The distribution of the 
endopeptidase processing enzymes (PTP 
(prohormone thiol protease), prohormone convertases 
1 and 2 (PC1 and PC2)) may vary in different tissue 
(Deftos et al., 2001). PTP cleaved the PTHLH 
precursor at the multibasic, dibasic, and monobasic 
residue cleavage sites to generate the NH2-terminal 
peptide (residues 1-37, having PTH-like and growth 
regulatory activities), the mid-region domain 
(residues 38-93, regulating calcium transport and cell 
proliferation), and the COOH-terminal domain 
(residues 102-141, modulating osteoclast activity) 
(Hook et al., 2001). 
Expression 
PTHLH is a protein polyhormone produced by most 
if not all tissues in the body. It is secreted during both 
fetal and postnatal life. Although PTHLH is found in 
the circulation, most of its activity appears to be
paracrine. 
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This diagram represents schematically one possible proteolytic processing pattern of PTHLH into 3 bioactive peptides. The mid-
region of PTHLH contains the nuclear localization signal (NLS). 
 
 
A complex of transcription factors and coactivators 
(CREB, Ets1 and CBP) regulates PTHLH 
transcription and may contribute to the alterations 
associated with the promotion of carcinogenesis 
(Hamzaoui et al., 2007). Disruption of the normal 
regulation during cancer progression may in part be 
associated with TGF-beta1-induced changes in 
PTHLH mRNA isoform expression and stability 
(Sellers et al., 2004). TGF-β activates PTHLH 
expression increasing transcription from the P3 
promoter through a synergistic interaction of Smad3 
and Ets1 (Lindemann et al., 2001). ERK1/ERK2-
dependent Ets2/PKCε synergism also appears to 
regulate PTHLH expression in breast cancer cells 
(Lindemann et al., 2003). 
The PTHLH gene is also under the transcriptional 
control of glucocorticoids and vitamin D (Ikeda et al., 
1989). 1,25-dihydroxy vitamin D3 treatment 
increases PTHLH mRNA expression and blocks the 
stimulatory effect of TGF-beta on PTHLH mRNA 
expression (Kunakornsawat et al., 2001). 
Glucocortical steroid hormone can suppress PTHLH 
mRNA expression and release of bioactive PTHLH in 
certain PTHLH-producing tumors (Kasono et al., 
1991). The regulation of PTHLH expression by 
female sex steroid hormones is still unclear 
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(Kurebayashi and Soono, 1997; Sugimoto et al., 
1999; Rabbani et al., 2005). 
Glucocorticoids reduced PTHLH and PTH1R 
expression in human mesenchymal stem cells which 
could be one of the mechanisms involved in steroids 
induced bone loss (Ahlström et al., 2009). 
In cell lines, upregulation of hypoxia induced factor 
HIF-2α subunit is involved in PTHLH upregulation 
(Manisterski et al., 2010). 
PTHLH is a downstream target for RAS and SRC (Li 
and Drucker, 1994), K-ras mutation increases 
PTHLH expression (Kamai et al., 2001) while a 
farnesyltransferase inhibitor known to inhibit RAS 
function can decrease PTHLH expression (Dackiw et 
al., 2005). The von Hippel-Lindau tumor suppressor 
protein also negatively regulates PTHLH expression 
at the post-transcriptional level (Massfelder et al.,
2004). 
Localisation 
PTHLH is a secreted polyhormone and is localized in 
the Golgi apparatus in the cytoplasm. However, in 
some cells, PTHLH can be detected in the nucleus by 
immunochemistry. The growth-inducing effect of 
NLS-containing mid-region PTHLH peptide in breast 
cancer is dependent on both internalization into the 
cytoplasm and subsequent translocation to the 
nucleus (Kumari et al., 2006). PTHLH travels from 
the cytosol to the nucleus with the help of the nuclear 
transport factor importin beta1. Importin beta1 
enhanced the association of PTHLH with 
microtubules, and the microtubule cytoskeleton plays 
an important role in protein transport to the nucles 
(Lam et al., 2002). 
The site of recognition of PTHLH is the N-terminal 
half of importin, which can also bind Ran and 
nucleoporin, and is sufficient for PTHLH nuclear 
import (Conti, 2003). 
Function 
PTHLH is a growth factor, a PTH-like calciotropic 
hormone, a developmental regulatory molecule, and a 
muscle relaxant (Clemens et al., 2001). The diverse 
activities of PTHLH result not only from processing 
of the precursor into multiple hormones, but from use 
of multiple receptors. 
It is clear that the Type 1 Parathyroid Hormone 
Receptor (PTH1R), binding both PTH (1-34) and 
PTHLH (1-36), is the receptor mediating the function 
of PTHLH (1-36), and it is the only cloned receptor 
for PTHLH so far (Clemens et al., 2001). 
PTHLH also binds to a type of receptor in some 
tissues that does not bind PTH. PTHLH (67-86) 
activates phospholipase C signaling pathways 
through a receptor distinct from that activated by 
PTHLH (1-36) in the same cells (Orloff et al., 1996). 
Unlike PTH, picomolar concentrations of the PTHLH 
(107-111) fragment to can activate membrane-
associated PKC in osteosarcoma cells (Gagnon et al., 
1993). PTHLH (107-139) exerts effects through the 
PKC/ERK pathway (de Gortázar et al., 2006). Thus, 
it is highly likely that the mid-region and osteostatin 
peptides bind other, unique receptors, but those 
receptors have yet to be cloned and identified. 
In contrast to the receptor-mediated endrocrine and 
paracrine action, the mid-region PTHLH peptide 
contains a classic bipartite nuclear localization signal 
(NLS) which upon entering the nuclear compartment 
confers "intracrine" actions. Details of the nuclear 
action of PTHLH are still lacking, but overall, nuclear 
PTHLH appears to be mitogenic (de Miguel et al., 
2001). The translation of PTHLH initiates from both 
the methionine-coding AUG and a leucine-coding 
CUGs further downstream in its signal sequence. It 
appeared that when translation was initiated from 
CUGs, PTHLH accumulated in the nucleoli, and that 
when translation was initiated from AUG, PTHLH 
localized in both the Golgi apparatus and nucleoli. 
Thus, nucleolar PTHLH appears to be derived from 
translation initiating from both AUG and CUGs 
(Amizuka et al., 2002). Modulation of cell adhesion 
by PTHLH localized in the nucleus is a normal 
physiological action of PTHLH, mediated by 
increasing integrin gene transcription (Anderson et 
al., 2007). The promotion by PTHLH in cancer 
growth and metastasis may be mediated by 
upregulating integrin alpha6beta4 expression and 
activating Akt (Shen and Falzon, 2006). 
PTHLH also interacts with beta-arrestin 1B, an 
important component of MAPK signaling and G-
protein-coupled receptor desensitization, and this 
interaction requires residues 122-141 of PTHLH. 
Therefore, beta-arrestin 1 may mediate a novel 
regulatory function of PTHLH in intracellular 
signaling (Conlan et al., 2002). 
PTHLH also play a major role in development of 
several tissues and organs.  
PTHLH stimulates the proliferation of chondrocytes 
and suppresses their terminal differentiation. PTHLH 
(107-139) is a substrate for secPHEX, and 
osteocalcin, pyrophosphate and phosphate are 
inhibitors of secPHEX activity; thus PHEX activity 
and PTHLH are part of a complex network regulating 
bone mineralization (Boileau et al., 2001). PTHLH 
plays a central role in the physiological regulation of 
bone formation, by promoting recruitment and 
survival of osteoblasts, and probably plays a role in 
the physiological regulation of bone resorption, by 
enhancing osteoclast formation.  
Signaling by fibroblast growth factor receptor 3 and 
PTHLH coordinate in cartilage and bone 
development (Amizuka et al., 2004). PTHLH is also 
an essential physiological regulator of adult bone 
mass (Bisello et al., 2004). 
In oophorectomized mice, injecting PTHLH 
fragments increased bone formation and reduced 
bone resorption (de Castro et al., 2012). 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(2) 97 
Subcutaneous PTHLH injections in healthy 
postmenopausal women resulted in a pure anabolic 
effect on bone and increase intestinal calcium 
absorption when given in high doses (Horwitz et al., 
2010). 
PTHLH maintains chondrocytes and growth plates as 
the inhibition of PTHLH signaling via PTH/PTHLH 
receptor in chondrocytes resulted in an accelerated 
differentiation of chondrocytes and premature 
disappearance of the growth plates (Hirai et al., 
2011). PTHLH signaling stimulates chrondrocytes 
proliferation. This process is inhibited via WNT/beta 
catenin signaling that in turn stimulates chondrocytes 
hypertrophy (Guo et al., 2009). 
In giant cell tumors, stromal cell production of 
PTHLH increased RANK ligand expression and led 
to giant cell formation (Cowan et al., 2012). 
PTHLH increased the survival of giant cell tumor 
stromal cells in vitro while the neutralization of 
PTHLH signaling induced cell death through the 
activation of different pathways (caspase, TRAIL, 
JAK-STAT, and cyclin E/CDK2) (Mak et al., 2012). 
PTHLH aids in normal mammary gland development 
and lactation as well as placental transfer of calcium. 
Mammary gland development depends upon a 
complex interaction between epithelial and 
mesenchymal cells that requires PTHLH. The 
calcium sensor (CaR) regulates PTHLH production as 
well as transport of calcium in the lactating mammary 
gland (Ardeshirpour et al., 2006). In normal animals, 
mammary epithelial cells secrete a lot of PTHLH, 
which helps to adjust maternal metabolism to meet 
the calcium demands of lactation. The mid-region 
PTHLH peptide has also been shown to control the 
normal maternal-to-fetal pumping of calcium across 
the placenta. 
Rarely, placental PTHLH production can lead to 
pregnancy associated hypercalcemia. Hypercalcemia 
in pregnancy could have significant morbidity but 
tend to resolve post-delivery (Eller-Vainicher et al., 
2012). 
PTHLH is secreted from smooth muscle in many 
organs, usually in response to stretching. PTHLH 
relaxes smooth muscle. Transgenic mice that express 
PTHLH in vascular smooth muscle have hypotension, 
being consistent with a vasodilating effect of PTHLH. 
PTHLH is highly expressed in the skin. EGF and 
other similar ligands can potentially activate PTHLH 
gene expression in the epidermis (Cho et al., 2004). 
PTHLH can inhibit hair growth and is required for 
tooth eruption as shown by mouse models that 
manipulated the PTHLH gene. 
In rodent and human pancreatic beta cell cultures, 
PTHLH (1-36) enhanced the proliferation and 
function of beta cells. Injecting male mice with 
PTHLH (1-36) increased beta cell proliferation via 
increased levels of cyclin D2 and decreased levels of 
Ink4a (Williams et al., 2011). 
PTHLH activates BMP-2/ Cbfa1 signaling pathway 
which could lead to vascular calcifications in 
hemodialysis patients (Liu et al., 2012). 
In addition, PTHLH overexpression increased arterial 
vascular smooth muscle cells proliferation resulting 
in arterial stenosis (Sicari et al., 2012). 
Implicated in 
Humoral hypercalcemia of malignancy 
Prognosis 
The median survival after the first occurrence of 
hypercalcemia is 66 days in patients with serum 
PTHLH ≤ 21 pmol/L and 33 days in patients with 
PTHLH > 21 pmol/L. In hypercalcemia of 
malignancy, raised serum levels of PTHLH indicate a 
more advanced tumor state and an extremely poor 
prognosis (Pecherstorfer et al., 1994). 
Oncogenesis 
Humoral hypercalcemia of malignancy (HHM) was 
first described by Albright in 1941 (Albright, 1941), 
and is a well-known complication among cancer 
patients. This syndrome is commonly encountered in 
advanced cancer of epithelial origin, especially 
squamous cell carcinoma of the lung. Studies of the 
"humors" secreted by cancer that causes 
hypercalcemia led to the discovery of 3 classes of 
peptides: parathyroid-like peptides, growth factor-like 
peptides, and bone-resorbing factors. Then protein 
purification led to molecular studies that cloned 
cDNAs for PTHLH (Suva et al., 1987; Broadus et al., 
1988; Mangin et al., 1988). Suva et al. (Suva et al., 
1987) suggested that the PTHLH may be responsible 
for the abnormal calcium metabolism in HHM.  
In the mammary epithelium of breast cancer mouse 
model, PTHLH inhibition delayed tumor formation 
and spread with reduction of markers of angiogenesis 
and cell proliferation (Li et al., 2011).  
PTHLH can be expressed in many tumors and leads 
to chemotherapy resistance as it inhibits apoptosis via 
downregulation of proapoptotic factors including 
Bax, and PUMA while upregulating antiapoptotic 
factors (Bcl-2, and Bcl-xl) (Gagiannis et al., 2009). 
Autocrine promotion of tumor 
progression 
Prognosis 
In the absence of hypercalcemia, approximately 17% 
of patients with gastroesophageal carcinoma have 
elevated levels of PTHLH, and the increase in 
PTHLH was associated with a poor prognosis (Deans 
et al., 2005). 
Oncogenesis 
mRNA for the PTH1R was detected many tumors 
expressing PTHLH; thus the PTHLH produced by 
these tumors may act in an autocrine or paracrine 
fashion (Southby et al., 1995; Alokail and Peddie, 
2007; Gessi et al., 2007).  
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The interactions among breast cancer cells, osteoblasts and osteoclasts define a feedback loop that promote breast cancer growth in 
the bone microenvironment. 
 
PTHLH (1-34) treatment resulted in an increase in 
proliferation in prostate cancer cells which may 
require androgen in some cell lines (Asadi et al., 
2001). In breast cancer cells, PTHLH regulates CDC2 
and CDC25B via PTH1R in a cAMP-independent 
manner, and PTHLH promotes cell migration through 
induction of ITGA6, PAI-1, and KISS-1, and 
promotes proliferation through induction of KISS-1 
(Dittmer et al., 2006). These pieces of evidence 
together suggest that PTHLH and PTH1R together 
play an important role in the autocrine/paracrine 





PTHLH is a mediator of the bone destruction 
associated with osteolytic metastasis. Patients with 
PTHLH-expressing breast carcinoma are more likely 
to develop bone metastasis, and bone metastasis 
expresses PTHLH in >90% of cases as compared 
with <20% of cases of metastasis to other sites 
(Powell et al., 1991). 
In breast cancer, osteolytic metastases are the most
common. PTHLH is a common osteolytic factor, and 
other osteolytic factors include vascular endothelial 
growth factor and interleukin 8 and interleukin 11. 
Since osteoblasts are the main regulators of osteolytic 
osteoclasts, stimulation of osteoblasts can 
paradoxically increase osteoclast function. 
Simultaneous expression of osteoblastic and 
osteolytic factors can produce mixed metastases. 
PTHLH expression by cancer cells may provide a 
selective growth advantage in bone because PTHLH 
stimulates osteoclastic bone resorption to release 
growth factors such as TGF-beta from the bone 
matrix. TGF-beta in turn will activate by osteoclastic 
bone resorption and enhance PTHLH expression and 
tumor cell growth (Yin et al., 1999), thus completing 
a vicious cycle (see diagram). Taken together, 
PTHLH expression by breast carcinoma cells enhance 
the development and progression of breast carcinoma 
metastasis to bone (Guise et al., 1996). Alternatively, 
cytokines such as IL-8 initiate the process of 
osteoclastic bone resorption in the early stages of 
breast cancer metastasis, and PTHLH expression is 
induced to stimulate the vicious cycle of osteolysis at 
a later stage (Bendre et al., 2003). 
Certain cancer treatments, especially sex steroid 
hormone deprivation therapies, stimulate bone loss. 
Bone resorption will result in the release of bone 
growth factors, which may inadvertently facilitate 
bone metastasis (Guise, 2000). Treatment with 
bisphosphonates will prevent bone resorption and 
reduce the release of bone growth factors (Guise et 
al., 2005). 
Cachexia in hypercalcemia of 
malignancy 
Oncogenesis 
PTHLH induces a wasting/cachectic syndrome 
(Iguchi et al., 2001). PTHLH leads to decreased 
physical activity and lowered energy metabolism 
independently of the effects of hypercalcemia and 
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proinflammatory cytokines (Onuma et al., 2005). In a 
rodent model, PTHLH induces a cachectic  
syndrome (in addition to inducing hypercalcemia of 
malignancy) by changing the mRNA levels of 
orexigenic and anorexigenic peptides, except leptin 
and orexin (Hashimoto et al., 2007). Expression of 
cachexia-inducing cytokines such as interleukin-6 
and leukemia inhibitory factor is increased by 
PTHLH (Iguchi et al., 2006). Animal data suggest 
that humanized antibody against PTHLH may be 
effective for patients with hypercalcemia and 
cachexia in patients with humoral hypercalcemia of 
malignancy (Sato et al., 2003). 
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